Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day
Cellectar Biosciences, Inc. (NASDAQ: CLRB) will present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day in New York City on May 13, 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cellectar Biosciences, Inc. (NASDAQ: CLRB) will present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day in New York City on May 13, 2024. Jarrod Longcor, the company's COO, will provide an overview of Cellectar in a fireside chat.
Details
News Market Reaction – CLRB
The recorded move for CLRB in the trading session of this news was -2.74%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating officer of Cellectar, will present an overview of the company in a fireside chat at the upcoming Guggenheim Healthcare Talks Radiopharmaceuticals Day being held on May 13, 2024 in New York City. Details of the fireside chat are as follows:
| Date: | Monday, May 13, 2024 |
| Time: | 1:00 pm Eastern Time |
| Webcast: | Click HERE |
A replay of the presentation will be available on the Events section of the company’s investor relations website.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company’s product pipeline includes lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
For more information, please visit www.cellectar.com and www.wmclinicaltrial.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.
Contacts
MEDIA:
Claire LaCagnina
Bliss Bio Health
315-765-1462
clacagnina@blissbiohealth.com
INVESTORS:
Chad Kolean
Chief Financial Officer
investors@cellectar.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.